Literature DB >> 31710943

Stereotactic MR-guided adaptive radiation therapy for peripheral lung tumors.

Tobias Finazzi1, Miguel A Palacios2, Cornelis J A Haasbeek2, Marjan A Admiraal2, Femke O B Spoelstra2, Anna M E Bruynzeel2, Berend J Slotman2, Frank J Lagerwaard2, Suresh Senan2.   

Abstract

BACKGROUND AND
PURPOSE: We studied the benefits of using stereotactic MR-guided adaptive radiation therapy (SMART) for delivery of SABR in peripherally located lung tumors. METHODS AND MATERIALS: Twenty-three patients (25 peripheral lung tumors) underwent SMART in 3-8 fractions on an MR Linac or Cobalt-60 system. Before each fraction, a breath-hold MR scan was acquired, followed by on-table plan adaptation based on the anatomy-of-the-day. Breath-hold gated delivery was performed under continuous MR-guidance using an in-room monitor. Benefits of on-table adaptation were studied by comparing 112 «predicted» plans, which are the baseline plans recalculated on the anatomy-of-the-day, with the on-table reoptimized plans.
RESULTS: The full SMART procedure took a median of 48 and 62 minutes on the MR Linac and Cobalt-60 system, respectively. Median SMART-PTVs were 9.5 cm3 (range, 3.1-55.6). In 14 patients who had undergone a free-breathing 4DCT, SMART-PTVs measured 53.7% (range, 31.9-75.0) of PTVs that would have been generated using a motion-encompassing internal target volume approach. On-table adaptation improved prescription dose coverage of the PTV from a median of 92.1% in predicted plans, to 95.0% in reoptimized ones, thereby increasing the proportion of fractions delivering ≥100 Gy (BED10Gy) to 95% of PTV, from 90.2% to 100.0%.
CONCLUSION: Delivery of gated breath-hold SABR using MR-guidance resulted in significantly smaller target volumes than would have been the case with an ITV-based approach. Although on-table adaptation ensured delivery of ablative doses in all fractions, the dosimetric benefits were modest, suggesting that daily online plan adaptation may not benefit most patients with peripheral lung tumors.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adaptive radiotherapy; Lung cancer; MR-guided radiation therapy; SABR

Mesh:

Year:  2019        PMID: 31710943     DOI: 10.1016/j.radonc.2019.10.013

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  21 in total

1.  Performance evaluation of a visual guidance patient-controlled respiratory gating system for respiratory-gated magnetic-resonance image-guided radiation therapy.

Authors:  Hyung Jin Choun; Jung-In Kim; Chang Heon Choi; Seongmoon Jung; Hyeongmin Jin; Hong-Gyun Wu; Eui Kyu Chie; Jong Min Park
Journal:  Phys Eng Sci Med       Date:  2022-06-20

2.  Magnetic resonance guided adaptive stereotactic body radiotherapy for lung tumors in ultracentral location: the MAGELLAN trial (ARO 2021-3).

Authors:  Sebastian Regnery; Jonas Ristau; Fabian Weykamp; Philipp Hoegen; Simon David Sprengel; Katharina Maria Paul; Carolin Buchele; Sebastian Klüter; Carolin Rippke; Claudia Katharina Renkamp; Moritz Pohl; Jan Meis; Thomas Welzel; Sebastian Adeberg; Stefan Alexander Koerber; Jürgen Debus; Juliane Hörner-Rieber
Journal:  Radiat Oncol       Date:  2022-05-25       Impact factor: 4.309

Review 3.  Target Definition in MR-Guided Adaptive Radiotherapy for Head and Neck Cancer.

Authors:  Mischa de Ridder; Cornelis P J Raaijmakers; Frank A Pameijer; Remco de Bree; Floris C J Reinders; Patricia A H Doornaert; Chris H J Terhaard; Marielle E P Philippens
Journal:  Cancers (Basel)       Date:  2022-06-20       Impact factor: 6.575

4.  Use of a healthy volunteer imaging program to optimize clinical implementation of stereotactic MR-guided adaptive radiotherapy.

Authors:  Patrick J Boyle; Elizabeth Huynh; Sara Boyle; Jennifer Campbell; Jessica Penney; Iquan Usta; Emily Neubauer Sugar; Fred Hacker; Christopher Williams; Daniel Cagney; Raymond Mak; Lisa Singer
Journal:  Tech Innov Patient Support Radiat Oncol       Date:  2020-11-29

5.  Treatment plan quality during online adaptive re-planning.

Authors:  Janita E van Timmeren; Madalyne Chamberlain; Jérôme Krayenbuehl; Lotte Wilke; Stefanie Ehrbar; Marta Bogowicz; Callum Hartley; Mariangela Zamburlini; Nicolaus Andratschke; Helena Garcia Schüler; Matea Pavic; Panagiotis Balermpas; Chaehee Ryu; Matthias Guckenberger; Stephanie Tanadini-Lang
Journal:  Radiat Oncol       Date:  2020-08-21       Impact factor: 3.481

6.  Delivery of magnetic resonance-guided single-fraction stereotactic lung radiotherapy.

Authors:  Tobias Finazzi; John R van Sörnsen de Koste; Miguel A Palacios; Femke O B Spoelstra; Berend J Slotman; Cornelis J A Haasbeek; Suresh Senan
Journal:  Phys Imaging Radiat Oncol       Date:  2020-05-20

Review 7.  MR-Guided Radiotherapy: The Perfect Partner for Immunotherapy?

Authors:  Juliane Hörner-Rieber; Sebastian Klüter; Jürgen Debus; Gosse Adema; Marleen Ansems; Marcel Verheij
Journal:  Front Oncol       Date:  2021-02-02       Impact factor: 6.244

8.  Patterns of practice for adaptive and real-time radiation therapy (POP-ART RT) part II: Offline and online plan adaption for interfractional changes.

Authors:  Jenny Bertholet; Gail Anastasi; David Noble; Arjan Bel; Ruud van Leeuwen; Toon Roggen; Michael Duchateau; Sara Pilskog; Cristina Garibaldi; Nina Tilly; Rafael García-Mollá; Jorge Bonaque; Uwe Oelfke; Marianne C Aznar; Ben Heijmen
Journal:  Radiother Oncol       Date:  2020-06-21       Impact factor: 6.280

9.  Markerless Real-Time 3-Dimensional kV Tracking of Lung Tumors During Free Breathing Stereotactic Radiation Therapy.

Authors:  Kimmie de Bruin; Max Dahele; Hassan Mostafavi; Berend J Slotman; Wilko F A R Verbakel
Journal:  Adv Radiat Oncol       Date:  2021-04-20

Review 10.  Medical physics challenges in clinical MR-guided radiotherapy.

Authors:  Christopher Kurz; Giulia Buizza; Guillaume Landry; Florian Kamp; Moritz Rabe; Chiara Paganelli; Guido Baroni; Michael Reiner; Paul J Keall; Cornelis A T van den Berg; Marco Riboldi
Journal:  Radiat Oncol       Date:  2020-05-05       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.